# A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer

> **NCT07678957** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** DS-8201

## Key facts

- **NCT ID:** NCT07678957
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678957, "A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*